Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CRISPR-Tweaked donor cells take on Hard-to-Treat blood cancers

NCT ID NCT04035434

Disease control Sponsor: CRISPR Therapeutics AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aimed to check safety and how well the treatment works, but it was stopped early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CTX110 (CRISPR-edited donor immune cells targeting CD19)
What this could lead to
If successful, this could point toward a readily available 'off-the-shelf' cell therapy for certain blood cancers, reducing the need for patient-specific treatments.
What could go wrong
The trial was terminated early, so data is limited. As an early-phase study, safety and effectiveness are not yet proven, and there are risks like graft-versus-host disease and severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

93 people

The number who actually took part.

Started

Jul 2019

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. For NHL patients: Age ≥18 years. For B cell ALL patients: age ≥18 years to ≤70 years 2. Refractory or relapsed non-Hodgkin lymphoma, as evidenced by 2 or more lines of prior therapy, or histologically confirmed B cell ALL, refractory or relapsed. 3. Eastern Cooperative Oncology Group performance status 0 or 1. 4. Adequate renal, liver, cardiac and pulmonary organ function 5. Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX110 infusion. Key Exclusion Criteria: 1. For NHL patients: prior allogeneic HSCT. For B cell ALL patients: prior allogeneic HSCT within 6 months, and/or any evidence of GvHD. 2. History of central nervous system (CNS) involvement by malignancy 3. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement. 4. Presence of bacterial, viral, or fungal infection that is uncontrolled. 5. Positive for HIV, or active hepatitis B virus or hepatitis C virus infection. 6. Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma, adequately resected and in situ carcinoma of cervix, or a previous malignancy that was completely resected and has been in remission for ≥5 years. 7. For NHL patients: Use of systemic anti-tumor therapy or investigational agent within 14 days or 5 half-lives, whichever is longer, of CTX110 infusion. For B cell ALL patients: Use of systemic antitumor therapy within 7 days of CTX110 infusion. 8. Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy. 9. Women who are pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult B cell ALL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell adult acute lymphocytic leukemia B-cell neoplasm Burkitt lymphoma leukemia lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult B cell ALL B-cell lymphoma B-cell malignancy Non-Hodgkin lymphoma

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • CHU de Lille

    Lille, 59000, France

  • Cedars Sinai

    Los Angeles, California, 90048, United States

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Duke University

    Durham, North Carolina, 27710, United States

  • Emory University Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • Hospital Clínic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hôpital Saint Antoine

    Paris, 75012, France

  • Institut Paoli-Calmettes

    Marseille, 13009, France

  • Markey Cancer Center, University of Kentucky

    Lexington, Kentucky, 40536, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Roswell Park Cancer Insitute

    Buffalo, New York, 14203, United States

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, 2050, Australia

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, 6009, Australia

  • Swedish Cancer Institute

    Seattle, Washington, 98104, United States

  • Texas Transplant Institute

    San Antonio, Texas, 78229, United States

  • UCSF Medical Center

    San Francisco, California, 94143, United States

  • University Hospital Würzburg

    Würzburg, 97080, Germany

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Hamburg

    Hamburg, 20148, Germany

  • University of Kansas

    Westwood, Kansas, 66205, United States

  • University of Maryland

    Baltimore, Maryland, 21201, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • Virginia Commonwealth University Massey Cancer Center

    Richmond, Virginia, 23298, United States

  • Washington University

    St Louis, Missouri, 63130, United States

  • Weill Cornell Medical College / New York Presbyterian Hospital

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.